News | Ablation Systems | May 10, 2017

Abbott Announces CE Mark for New Cardiac Ablation Catheter

TactiCath Contact Force Ablation Catheter, Sensor Enabled, integrates with EnSite Precision 3-D mapping system to enhance treatment of atrial fibrillation

Abbott Announces CE Mark for New Cardiac Ablation Catheter

May 10, 2017 — Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier for physicians to more effectively treat atrial fibrillation (AF). When integrated with Abbott's EnSite Precision cardiac mapping system, physicians are able to utilize dual impedance and magnetic technologies to help more precisely model the heart. This integrated system also helps physicians determine where to apply optimal contact force (pressure) when creating a lesion during a cardiac ablation to correct a heart rhythm abnormality. The Sensor Enabled technology allows physicians to create a more detailed heart model during ablation procedures than a catheter without a sensor.

Arrhythmias develop when electrical signals that regulate heart rhythms become disrupted or change, making the heart develop an irregular heartbeat. A patient with AF is at increased risk for stroke because the rapid heartbeat can let blood pool in the heart, which can cause clots to form and travel to the brain. To restore optimal electrical signals in the heart, ablation catheters deliver radio-frequency energy to cardiac tissue, creating small scars or lesions to areas responsible for generating arrhythmias. Not all ablation technology is the same, however, and recent research has continued to show the importance of applying optimal contact force to the heart during ablation procedures. Too much pressure applied to heart tissue can result in complications, yet if not enough pressure is applied the lesion may not be effective enough to stop the erratic signals in the heart.

"The TactiCath Contact Force Ablation Catheter, Sensor Enabled along with the EnSite Precision cardiac mapping system create a powerful combination for more precisely treating patients with cardiac arrhythmias," said Martin Lowe, M.D., clinical director of cardiac electrophysiology at Bart's Heart Centre at St. Bartholomew's Hospital in London. "Feeling confident in the accuracy of the contact force reading allows me to target the optimal pressure for creating effective and safe lesions."

The device is an update to the TactiCath Contact Force Catheter family. The clinical evidence show use of optimal Contact Force-guided AF ablation with the TactiCath Quartz catheter resulted in clinical success in 85.5 percent of patients and fewer post-ablation clinical events, translating to a 15 percent reduction in post-ablation management costs ($3,402 savings per patient) in the year after ablation versus patients treated with a non-contact force ablation catheter.

The magnetic sensor of the catheter integrates with the Abbott EnSite Precision cardiac mapping system, providing the ability to collect both magnetic and impedance (resistance) data so physicians can create more life-like models of the heart. It also uses the Abbott FlexAbility catheter platform's advanced ergonomic handle-shaft combination, which is designed for reach, maneuverability and 1:1 torque.

When utilized with EnSite Precision, the TactiCath Contact Force Ablation Catheter, Sensor Enabled can improve workflow efficiency in the lab. The system enables automated guidance of lesion marking, verification of the ablation catheter stability, the ability to automatically record the precise location of the catheter tip during radiofrequency energy application, the capability to add mapping points based on Contact Force, and the ability to review and identify any potential gaps by viewing specific lesions from the display list.

Currently the TactiCath Contact Force Ablation Catheter, Sensor Enabled is available in select markets in Europe, with full market release expected in the third quarter. Abbott is pursuing approval in the U.S.

For more information: www.abbott.com

Related Content

Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath
Technology | Ablation Systems | May 08, 2018
Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the United States....
Stereotaxis and Acutus Medical Announce Strategic Collaboration
News | Ablation Systems | May 04, 2018
Stereotaxis and Acutus Medical announced a strategic collaboration to integrate the Stereotaxis Niobe Magnetic...
Medtronic Cryoballoon Shows Positive Results for Patients With Persistent Atrial Fibrillation
News | Ablation Systems | April 12, 2018
Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance...
Boston Scientific Acquires Securus Medical Group Inc.
News | Ablation Systems | April 04, 2018
Boston Scientific Corp. announced the acquisition of Securus Medical Group Inc., a privately-held company that has...
Overlay Init